Biologics for bone regeneration: advances in cell, protein, gene, and mRNA therapies

Abstract

Bone fractures represent a significant global healthcare burden. Although fractures typically heal on their own, some fail to regenerate properly, leading to nonunion, a condition that causes prolonged disability, morbidity, and mortality. The challenge of treating nonunion fractures is further complicated in patients with underlying bone disorders where systemic and local factors impair bone healing. Traditional treatment approaches, including autografts, allografts, xenografts, and synthetic biomaterials, face limitations such as donor site pain, immune rejection, and insufficient mechanical strength, underscoring the need for alternative strategies. Biologic therapies have emerged as promising tools to enhance bone regeneration by leveraging the body’s natural healing processes. This review explores the critical role of conventional and emerging biologics in fracture healing. We categorize biologic therapies into protein-based treatments, gene and transcript therapies, small molecules, peptides, and cell-based therapies, highlighting their mechanisms of action, advantages, and clinical relevance. Finally, we examine the potential applications of biologics in treating fractures associated with bone disorders such as osteoporosis, osteogenesis imperfecta, rickets, osteomalacia, Paget’s disease, and bone tumors. By integrating biologic therapies with existing biomaterial-based strategies, these innovative approaches have the potential to transform clinical management and improve outcomes for patients with difficult-to-heal fractures.

References

[1] Collaborators, G. M. D. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry, 2022, 9: 137-150

[2] Calori G, Mazza E, Colombo M, Ripamonti C, Tagliabue L. Treatment of long bone non-unions with polytherapy: indications and clinical results. Injury, 2011, 42: 587-590

[3] Frölke JPM, Patka P. Definition and classification of fracture non-unions. Injury, 2007, 38: S19-S22

[4] Santolini E, West R, Giannoudis PV. Risk factors for long bone fracture non-union: a stratification approach based on the level of the existing scientific evidence. Injury, 2015, 46: S8-S19

[5] Mathieu M, et al.. Decreased pool of mesenchymal stem cells is associated with altered chemokines serum levels in atrophic nonunion fractures. Bone, 2013, 53: 391-398

[6] Heaney RP, Recker RR, Saville PD. Menopausal changes in bone remodeling. J. Lab. Clin. Med., 1978, 92: 964-970

[7] Coipeau P, et al.. Impaired differentiation potential of human trabecular bone mesenchymal stromal cells from elderly patients. Cytotherapy, 2009, 11: 584-594

[8] Eriksen EF, et al.. Cancellous bone remodeling in type I (postmenopausal) osteoporosis: quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels. J. Bone Miner. Res., 1990, 5: 311-319

[9] Mills LA, Aitken SA, Simpson AHR. The risk of non-union per fracture: current myths and revised figures from a population of over 4 million adults. Acta Orthop., 2017, 88: 434-439

[10] Dahabreh Z, Calori G, Kanakaris N, Nikolaou V, Giannoudis P. A cost analysis of treatment of tibial fracture nonunion by bone grafting or bone morphogenetic protein-7. Int. Orthop., 2009, 33: 1407-1414

[11] Athanasiou VT, et al.. Histological comparison of autograft, allograft-DBM, xenograft, and synthetic grafts in a trabecular bone defect: an experimental study in rabbits. Med. Sci. Monit., 2009, 16: BR24-BR31

[12] Pereira HF, Cengiz IF, Silva FS, Reis RL, Oliveira JM. Scaffolds and coatings for bone regeneration. J. Mater. Sci. Mater. Med, 2020, 31: 27

[13] Dahabreh Z, Dimitriou R, Giannoudis PV. Health economics: a cost analysis of treatment of persistent fracture non-unions using bone morphogenetic protein-7. Injury, 2007, 38: 371-377

[14] Paul L, et al.. Selection of massive bone allografts using shape-matching 3-dimensional registration. Acta Orthop., 2010, 81: 250-255

[15] Putzer D, Coraça-Huber D, Wurm A, Schmoelz W, Nogler M. Optimizing the grain size distribution of allografts in bone impaction grafting. J. Orthop. Res., 2014, 32: 1024-1029

[16] Coquelin L, et al.. In vivo and in vitro comparison of three different allografts vitalized with human mesenchymal stromal cells. Tissue Eng. Part A, 2012, 18: 1921-1931

[17] Aro HT, Aho AJ. Clinical use of bone allografts. Ann. Med., 1993, 25: 403-412

[18] Kim Y, Nowzari H, Rich SK. Risk of prion disease transmission through bovine-derived bone substitutes: a systematic review. Clin. Implant Dent. Relat. Res., 2013, 15: 645-653

[19] Pountos I, Giannoudis PV. Is there a role of coral bone substitutes in bone repair?. Injury, 2016, 47: 2606-2613

[20] Bertol LS, Schabbach R, dos Santos LAL. Dimensional evaluation of patient-specific 3D printing using calcium phosphate cement for craniofacial bone reconstruction. J. Biomater. Appl., 2017, 31: 799-806

[21] Lodoso-Torrecilla I, et al.. Multimodal pore formation in calcium phosphate cements. J. Biomed. Mater. Res. A, 2018, 106: 500-509

[22] Stanovici J, et al.. Bone regeneration strategies with bone marrow stromal cells in orthopaedic surgery. Curr. Res. Transl. Med., 2016, 64: 83-90

[23] Balmayor ER, Van Griensven M. Gene therapy for bone engineering. Front. Bioeng. Biotechnol., 2015, 3: 9

[24] Eftekhari, Z. et al. Advancements and challenges in mRNA and ribonucleoprotein-based therapies: from delivery systems to clinical applications. Mol. Ther.-Nucleic Acids35, 102313 (2024).

[25] De la Vega RE, et al.. Gene therapy for bone healing: lessons learned and new approaches. Transl. Res., 2021, 236: 1-16

[26] Kowalski PS, Rudra A, Miao L, Anderson DG. Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Mol. Ther., 2019, 27: 710-728

[27] Yin J, Luan S. Opportunities and challenges for the development of polymer-based biomaterials and medical devices. Regen. Biomater., 2016, 3: 129-135

[28] Li W, Szoka FC. Lipid-based nanoparticles for nucleic acid delivery. Pharm. Res., 2007, 24: 438-449

[29] Ghassemi T, et al.. Current concepts in scaffolding for bone tissue engineering. Arch. bone Jt. Surg., 2018, 6: 90

[30] Sfeir, C., Ho, L., Doll, B. A., Azari, K. & Hollinger, J. O. in Bone Regeneration and Repair 21–44 (Springer, 2005).

[31] Devescovi V, Leonardi E, Ciapetti G, Cenni E. Growth factors in bone repair. La Chirurgia Degli Organ. di Mov., 2008, 92: 161-168

[32] Katagiri, T., Tsukamoto, S., Osawa, K. & Kokabu, S. in A Tissue Regeneration Approach to Bone and Cartilage Repair 1–15 (Springer, 2015).

[33] Ozaki A, Tsunoda M, Kinoshita S, Saura R. Role of fracture hematoma and periosteum during fracture healing in rats: interaction of fracture hematoma and the periosteum in the initial step of the healing process. J. Orthop. Sci., 2000, 5: 64-70

[34] Schmidt-Bleek K, et al.. Inflammatory phase of bone healing initiates the regenerative healing cascade. Cell tissue Res., 2012, 347: 567-573

[35] Einhorn TA, Majeska RJ, Rush EB, Levine PM, Horowitz MC. The expression of cytokine activity by fracture callus. J. Bone Miner. Res., 1995, 10: 1272-1281

[36] Granero-Moltó F, et al.. Regenerative effects of transplanted mesenchymal stem cells in fracture healing. Stem cells, 2009, 27: 1887-1898

[37] Zhang H, et al.. Acceleration of fracture healing by overexpression of basic fibroblast growth factor in the mesenchymal stromal cells. Stem Cells Transl. Med., 2017, 6: 1880-1893

[38] Kodama J, Wilkinson KJ, Iwamoto M, Otsuru S, Enomoto-Iwamoto M. The role of hypertrophic chondrocytes in regulation of the cartilage-to-bone transition in fracture healing. Bone Rep., 2022, 17: 101616

[39] Vimalraj S. Alkaline phosphatase: structure, expression and its function in bone mineralization. Gene, 2020, 754: 144855

[40] Ghimire S, et al.. The investigation of bone fracture healing under intramembranous and endochondral ossification. Bone Rep., 2021, 14 100740

[41] Zhu S, Chen W, Masson A, Li Y-P. Cell signaling and transcriptional regulation of osteoblast lineage commitment, differentiation, bone formation, and homeostasis. Cell Discov., 2024, 10: 71

[42] Ford JL, Robinson DE, Scammell BE. The fate of soft callus chondrocytes during long bone fracture repair. J. Orthop. Res., 2003, 21: 54-61

[43] Buckwalter, J. Healing of the musculoskeletal tissues. Rockwood and Green’s fractures in adults (1991).

[44] Einhorn TA. The cell and molecular biology of fracture healing. Clin. Orthop. Relat. Res.®, 1998, 355: S7-S21

[45] Moucha, C. S. & Einhorn, T. A. in Bone Regeneration and Repair 169–194 (Springer, 2005).

[46] Schlickewei, C. W. et al. Current and future concepts for the treatment of impaired fracture healing. Int. J. Mol. Sci.20, 5805 (2019).

[47] Balmayor ER, et al.. Chemically modified RNA induces osteogenesis of stem cells and human tissue explants as well as accelerates bone healing in rats. Biomaterials, 2016, 87: 131-146

[48] Perez JR, et al.. Tissue engineering and cell-based therapies for fractures and bone defects. Front. Bioeng. Biotechnol., 2018, 6: 105

[49] Cheng H, et al.. Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). JBJS, 2003, 85: 1544-1552

[50] Liu Z, Luyten F, Lammens J, Dequeker J. Molecular signaling in bone fracture healing and distraction osteogenesis. Histol. Histopathol., 1999, 14: 587-595

[51] Onishi T, et al.. Distinct and overlapping patterns of localization of bone morphogenetic protein (BMP) family members and a BMP type II receptor during fracture healing in rats. Bone, 1998, 22: 605-612

[52] Bolander ME. Regulation of fracture repair by growth factors. Proc. Soc. Exp. Biol. Med., 1992, 200: 165-170

[53] Murakami M, et al.. FGF-dependent regulation of VEGF receptor 2 expression in mice. J. Clin. Invest., 2011, 121: 2668-2678

[54] Naganawa T, et al.. Reduced expression and function of bone morphogenetic protein-2 in bones of Fgf2 null mice. J. Cell. Biochem., 2008, 103: 1975-1988

[55] Xie H, et al.. PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis. Nat. Med., 2014, 20: 1270-1278

[56] Wang F, et al.. PDGFR in PDGF-BB/PDGFR signaling pathway does orchestrates osteogenesis in a temporal manner. Research, 2023, 6 0086

[57] Caplan AI, Correa D. PDGF in bone formation and regeneration: new insights into a novel mechanism involving MSCs. J. Orthop. Res., 2011, 29: 1795-1803

[58] de Oliveira JCS, et al.. Evaluation of the osteoinductive effect of PDGF-BB associated with different carriers in bone regeneration in bone surgical defects in rats. Implant Dent., 2017, 26: 559-566

[59] Kim HJ, et al.. In ovariectomy-induced osteoporotic rat models, BMP-2 substantially reversed an impaired alveolar bone regeneration whereas PDGF-BB failed. Clin. Oral. Investig., 2021, 25: 6159-6170

[60] Del Rosario C, Rodriguez-Evora M, Reyes R, Delgado A, Evora C. BMP-2, PDGF-BB, and bone marrow mesenchymal cells in a macroporous β-TCP scaffold for critical-size bone defect repair in rats. Biomed. Mater., 2015, 10: 045008

[61] Wu M, Chen G, Li Y-P. TGF-β and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease. Bone Res., 2016, 4: 16009

[62] Steinbrech DS, et al.. Gene expression of TGF-β, TGF-β receptor, and extracellular matrix proteins during membranous bone healing in rats. Plast. Reconstr. Surg., 2000, 105: 2028-2038

[63] Sarahrudi K, et al.. Elevated transforming growth factor-beta 1 (TGF-β1) levels in human fracture healing. Injury, 2011, 42: 833-837

[64] Massague J. The transforming growth factor-beta family. Annu. Rev. Cell Biol., 1990, 6: 597-641

[65] Xian L, et al.. Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells. Nat. Med., 2012, 18: 1095

[66] Andrew J, Hoyland J, Freemont A, Marsh D. Insulinlike growth factor gene expression in human fracture callus. Calcif. tissue Int., 1993, 53: 97-102

[67] Yakar S, Werner H, Rosen CJ. 40 YEARS OF IGF1: Insulin-like growth factors: actions on the skeleton. J. Mol. Endocrinol., 2018, 61: T115-T137

[68] Street J, et al.. Is human fracture hematoma inherently angiogenic?. Clin. Orthop. Relat. Res., 2000, 378: 224-237

[69] Ancelin M, et al.. Vascular endothelial growth factor VEGF189 induces human neutrophil chemotaxis in extravascular tissue via an autocrine amplification mechanism. Lab. Invest., 2004, 84: 502-512

[70] Martino MM, Briquez PS, Ranga A, Lutolf MP, Hubbell JA. Heparin-binding domain of fibrin (ogen) binds growth factors and promotes tissue repair when incorporated within a synthetic matrix. Proc. Natl. Acad. Sci., 2013, 110: 4563-4568

[71] Hu K, Olsen BR. The roles of vascular endothelial growth factor in bone repair and regeneration. Bone, 2016, 91: 30-38

[72] Beamer B, Hettrich C, Lane J. Vascular endothelial growth factor: an essential component of angiogenesis and fracture healing. HSS J., 2010, 6: 85-94

[73] Grills BL, Schuijers JA. Immunohistochemical localization of nerve growth factor in fractured and unfractured rat bone. Acta Orthop. Scand., 1998, 69: 415-419

[74] Hukkanen M, et al.. Rapid proliferation of calcitonin gene-related peptide-immunoreactive nerves during healing of rat tibial fracture suggests neural involvement in bone growth and remodelling. Neuroscience, 1993, 54: 969-979

[75] Li Z, et al.. Fracture repair requires TrkA signaling by skeletal sensory nerves. J. Clin. Invest., 2019, 129: 5137-5150

[76] Parker RS, et al.. Role of the neurologic system in fracture healing: an extensive review. Curr. Osteoporos. Rep., 2024, 22: 205-216

[77] Madsen JE, et al.. Fracture healing and callus innervation after peripheral nerve resection in rats. Clin. Orthop. Relat. Res., 1998, 351: 230-240

[78] Nordsletten L, et al.. The neuronal regulation of fracture healing: effects of sciatic nerve resection in rat tibia. Acta Orthop. Scand., 1994, 65: 299-304

[79] Taghi GM, Maryam GK, Taghi L, Leili H, Leyla M. Characterization of in vitro cultured bone marrow and adipose tissue-derived mesenchymal stem cells and their ability to express neurotrophic factors. Cell Biol. Int., 2012, 36: 1239-1249

[80] Nakanishi T, et al.. Expression of nerve growth factor family neurotrophins in a mouse osteoblastic cell line. Biochem. Biophys. Res. Commun., 1994, 198: 891-897

[81] Stapledon CJ, et al.. Human osteocyte expression of nerve growth factor: the effect of pentosan polysulphate sodium (PPS) and implications for pain associated with knee osteoarthritis. PLoS One, 2019, 14: e0222602

[82] Takano S, et al.. Nerve growth factor regulation by TNF-α and IL-1β in synovial macrophages and fibroblasts in osteoarthritic mice. J. Immunol. Res., 2016, 2016 5706359

[83] Li R, Stewart DJ, von Schroeder HP, Mackinnon ES, Schemitsch EH. Effect of cell-based VEGF gene therapy on healing of a segmental bone defect. J. Orthop. Res., 2009, 27: 8-14

[84] Vukicevic, S., Sampath, K. T., Grgurevic, L., Cohen, C. & Opperman, H. (Google Patents, 2019).

[85] Cahill KS, McCormick PC, Levi AD. A comprehensive assessment of the risk of bone morphogenetic protein use in spinal fusion surgery and postoperative cancer diagnosis. J. Neurosurg. Spine, 2015, 23: 86-93

[86] James AW, et al.. A review of the clinical side effects of bone morphogenetic protein-2. Tissue Eng. B Rev., 2016, 22: 284-297

[87] Kuroda Y, et al.. Recombinant human FGF-2 for the treatment of early-stage osteonecrosis of the femoral head: TRION, a single-arm, multicenter, Phase II trial. Regen. Med., 2021, 16: 535-548

[88] Kawaguchi H, et al.. Local application of recombinant human fibroblast growth factor-2 on bone repair: a dose–escalation prospective trial on patients with osteotomy. J. Orthop. Res., 2007, 25: 480-487

[89] Nevins M, Camelo M, Nevins ML, Schenk RK, Lynch SE. Periodontal regeneration in humans using recombinant human platelet-derived growth factor-BB (rhPDGF-BB) and allogenic bone. J. Periodontol., 2003, 74: 1282-1292

[90] Younger A, Penner M, Montijo HE. Vancouver experience of recombinant human platelet-derived growth factor. Foot Ankle Clin., 2016, 21: 771-776

[91] DiGiovanni CW, et al.. The importance of sufficient graft material in achieving foot or ankle fusion. JBJS, 2016, 98: 1260-1267

[92] Haines MS, et al.. Sequential therapy with recombinant human IGF-1 followed by risedronate increases spine bone mineral density in women with anorexia nervosa: a randomized, placebo-controlled trial. J. Bone Miner. Res., 2021, 36: 2116-2126

[93] Howell TH, et al.. A phase I/II clinical trial to evaluate a combination of recombinant human platelet-derived growth factor-BB and recombinant human insulin-like growth factor-I in patients with periodontal disease. J. Periodontol., 1997, 68: 1186-1193

[94] Nevins M, et al.. Platelet-derived growth factor stimulates bone fill and rate of attachment level gain: results of a large multicenter randomized controlled trial. J. Periodontol., 2005, 76: 2205-2215

[95] Saag KG, et al.. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six–month results of a randomized, double-blind, controlled trial. Arthritis Rheumatism, 2009, 60: 3346-3355

[96] Neer RM, et al.. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med., 2001, 344: 1434-1441

[97] Komatsubara S, et al.. Human parathyroid hormone (1–34) accelerates the fracture healing process of woven to lamellar bone replacement and new cortical shell formation in rat femora. Bone, 2005, 36: 678-687

[98] Cosman F, et al.. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J. Bone Miner. Res., 2001, 16: 925-931

[99] Mancilla EE, Brodsky JL, Mehta S, Pignolo RJ, Levine MA. Teriparatide as a systemic treatment for lower extremity nonunion fractures: a case series. Endocr. Pract., 2015, 21: 136-142

[100] Chintamaneni S, Finzel K, Gruber B. Successful treatment of sternal fracture nonunion with teriparatide. Osteoporos. Int., 2010, 21: 1059-1063

[101] Kastirr I, et al.. Therapy of aseptic nonunions with parathyroid hormone. Eur. J. Orthop. Surg. Traumatol., 2019, 29: 169-173

[102] Johansson T. PTH 1-34 (teriparatide) may not improve healing in proximal humerus fractures: a randomized, controlled study of 40 patients. Acta Orthop., 2016, 87: 79-82

[103] Bhandari M, et al.. Does teriparatide improve femoral neck fracture healing: results from a randomized placebo-controlled trial. Clin. Orthop. Relat. Res., 2016, 474: 1234-1244

[104] Ciurlia E, Leali PT, Doria C. Use of teriparatide off-label: our experience and review of literature. Clin. Cases Miner. Bone Metab., 2017, 14: 28

[105] Kim JB, et al.. Bone regeneration is regulated by Wnt signaling. J. Bone Miner. Res., 2007, 22: 1913-1923

[106] Hadjiargyrou M, Kotsiopriftis M, Lauzier D, Hamdy RC, Kloen P. Activation of Wnt signaling in human fracture callus and nonunion tissues. Bone Rep., 2024, 22: 101780

[107] Minear S, et al.. Wnt proteins promote bone regeneration. Sci. Transl. Med., 2010, 2: 29ra30-29ra30

[108] Suen PK, et al.. Sclerostin monoclonal antibody enhanced bone fracture healing in an open osteotomy model in rats. J. Orthop. Res., 2014, 32: 997-1005

[109] Uemura T, et al.. Bone healing of distal radius nonunion treated with bridge plating with bone graft substitutes in combination with systemic romosozumab administration: a case report. Jt. Dis. Relat. Surg., 2021, 32: 526

[110] Shakeri A, Adanty C. Romosozumab (sclerostin monoclonal antibody) for the treatment of osteoporosis in postmenopausal women: a review. J. Popul. Ther., 2020, 27: e25-e31

[111] Bhandari M, et al.. Romosozumab in skeletally mature adults with a fresh unilateral tibial diaphyseal fracture: a randomized phase-2 study. JBJS, 2020, 102: 1416-1426

[112] Schemitsch EH, et al.. A randomized, placebo-controlled study of romosozumab for the treatment of hip fractures. JBJS, 2020, 102: 693-702

[113] Glinka A, et al.. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature, 1998, 391: 357-362

[114] Butler JS, et al.. Silencing Dkk1 expression rescues dexamethasone-induced suppression of primary human osteoblast differentiation. BMC Musculoskelet. Disord., 2010, 11: 1-10

[115] Agholme F, Isaksson H, Kuhstoss S, Aspenberg P. The effects of Dickkopf-1 antibody on metaphyseal bone and implant fixation under different loading conditions. Bone, 2011, 48: 988-996

[116] Jin H, et al.. Anti-DKK1 antibody promotes bone fracture healing through activation of β-catenin signaling. Bone, 2015, 71: 63-75

[117] Lacey D, et al.. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 1998, 93: 165-176

[118] Törring O. Effects of denosumab on bone density, mass and strength in women with postmenopausal osteoporosis. Ther. Adv. Musculoskelet. Dis., 2015, 7: 88-102

[119] Papapoulos S, et al.. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos. Int., 2015, 26: 2773-2783

[120] Shiva P. Effect of denosumab injection in early union and consolidation of callus in aseptic tibial shaft non-union. J. Pharm. Res., 2024, 23: 35

[121] Garrison, K. R. et al. Clinical effectiveness and cost-effectiveness of bone morphogenetic proteins in the non-healing of fractures and spinal fusion: a systematic review. Health Technology Assessment (Winchester, England)11, 1–150, iii (2007).

[122] Kanakaris N, Giannoudis PV. The health economics of the treatment of long-bone non-unions. Injury, 2007, 38: S77-S84

[123] Kamionka M. Engineering of therapeutic proteins production in Escherichia coli. Curr. Pharm. Biotechnol., 2011, 12: 268-274

[124] Zaman R, et al.. Current strategies in extending half-lives of therapeutic proteins. J. Control. Release, 2019, 301: 176-189

[125] Beygmoradi A, Homaei A, Hemmati R, Fernandes P. Recombinant protein expression: challenges in production and folding related matters. Int. J. Biol. Macromol., 2023, 233: 123407

[126] Evans CH, Ghivizzani SC, Robbins PD. Orthopaedic gene therapy: twenty-five years on. JBJS Rev., 2021, 9 e20

[127] Rao GA, Buethe DD. Plasmid based gene delivery for orthopedic disorders: a brief review. J. Drug Target., 2004, 12: 341-345

[128] Park J, et al.. Bone regeneration in critical size defects by cell-mediated BMP-2 gene transfer: a comparison of adenoviral vectors and liposomes. Gene Ther., 2003, 10: 1089-1098

[129] Osawa K, Okubo Y, Nakao K, Koyama N, Bessho K. Osteoinduction by microbubble-enhanced transcutaneous sonoporation of human bone morphogenetic protein-2. J. Gene Med., 2009, 11: 633-641

[130] Wang JC, et al.. Effect of regional gene therapy with bone morphogenetic protein-2-producing bone marrow cells on spinal fusion in rats. JBJS, 2003, 85: 905-911

[131] Van Griensven M, et al.. Adenoviral gene transfer in a rat fracture model. Lab. Anim., 2002, 36: 455-461

[132] Wilkinson P, et al.. Systematic review of the preclinical technology readiness of orthopedic gene therapy and outlook for clinical translation. Front. Bioeng. Biotechnol., 2021, 9 626315

[133] Bozo I, Deev R, Drobyshev A, Isaev A, Eremin I. World’s first clinical case of gene-activated bone substitute application. Case Rep. Dent., 2016, 2016: 8648949

[134] Ranjbarnejad F, Khazaei M, Shahryari A, Khazaei F, Rezakhani L. Recent advances in gene therapy for bone tissue engineering. J. Tissue Eng. Regen. Med., 2022, 16: 1121-1137

[135] Masgutov R, et al.. Use of gene-activated demineralized bone allograft in the therapy of ulnar pseudarthrosis. Case report. BioNanoScience, 2017, 7: 194-198

[136] Evans CH, Ghivizzani S, Robbins PD. Orthopedic gene therapy—lost in translation?. J. Cell. Physiol., 2012, 227: 416-420

[137] Argintar E, Edwards S, Delahay J. Bone morphogenetic proteins in orthopaedic trauma surgery. Injury, 2011, 42: 730-734

[138] Evans CH. The vicissitudes of gene therapy. Bone Jt. Res., 2019, 8: 469-471

[139] Weissman D. mRNA transcript therapy. Expert Rev. Vaccines, 2015, 14: 265-281

[140] Wang Y-S, et al.. mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications. J. Biomed. Sci., 2023, 30 84

[141] Huysmans H, et al.. Expression kinetics and innate immune response after electroporation and LNP-mediated delivery of a self-amplifying mRNA in the skin. Mol. Ther. -Nucleic Acids, 2019, 17: 867-878

[142] Kormann MS, et al.. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat. Biotechnol., 2011, 29: 154-157

[143] Zhang W, et al.. An improved, chemically modified RNA encoding BMP-2 enhances osteogenesis in vitro and in vivo. Tissue Eng. Part A, 2019, 25: 131-144

[144] Andrée L, Yang F, Brock R, Leeuwenburgh S. Designing biomaterials for the delivery of RNA therapeutics to stimulate bone healing. Mater. Today Bio, 2021, 10: 100105

[145] Runzer CDT, et al.. Cellular uptake of modified mRNA occurs via caveolae-mediated endocytosis, yielding high protein expression in slow-dividing cells. Mol. Ther. -Nucleic Acids, 2023, 32: 960-979

[146] Wang P, et al.. Co-delivery of NS1 and BMP2 mRNAs to murine pluripotent stem cells leads to enhanced BMP-2 expression and osteogenic differentiation. Acta Biomater., 2020, 108: 337-346

[147] Balmayor ER, et al.. Modified mRNA for BMP-2 in combination with biomaterials serves as a transcript-activated matrix for effectively inducing osteogenic pathways in stem cells. Stem Cells Dev., 2017, 26: 25-34

[148] Fayed O, van Griensven M, Tahmasebi Birgani Z, Plank C, Balmayor ER. Transcript-activated coatings on titanium mediate cellular osteogenesis for enhanced osteointegration. Mol. Pharm., 2021, 18: 1121-1137

[149] Khorsand B, et al.. A comparative study of the bone regenerative effect of chemically modified RNA encoding BMP-2 or BMP-9. AAPS J., 2017, 19: 438-446

[150] De La Vega RE, et al.. Efficient healing of large osseous segmental defects using optimized chemically modified messenger RNA encoding BMP-2. Sci. Adv., 2022, 8 eabl6242

[151] Zhang M, et al.. Enhancement of bone regeneration by coadministration of angiogenic and osteogenic factors using messenger RNA. Inflamm. Regen., 2023, 43 32

[152] Halioua-Haubold C-L, et al.. Focus: genome editing: regulatory considerations for gene therapy products in the US, EU, and Japan. Yale J. Biol. Med., 2017, 90: 683

[153] Evans CH, Huard J. Gene therapy approaches to regenerating the musculoskeletal system. Nat. Rev. Rheumatol., 2015, 11: 234-242

[154] Li B. MicroRNA regulation in osteogenic and adipogenic differentiation of bone mesenchymal stem cells and its application in bone regeneration. Curr. Stem cell Res. Ther., 2018, 13: 26-30

[155] Nakasa T, Yoshizuka M, Andry Usman M, Elbadry Mahmoud E, Ochi M. MicroRNAs and bone regeneration. Curr. Genomics, 2015, 16: 441-452

[156] Groven RV, et al.. Early total care and damage control orthopaedics result in partially contrasting patterns of microRNA expression at the fracture site and in the systemic circulation: an animal study. Bone Jt. J., 2025, 107: 193-203

[157] Fang S, Deng Y, Gu P, Fan X. MicroRNAs regulate bone development and regeneration. Int. J. Mol. Sci., 2015, 16: 8227-8253

[158] Liu Z, et al.. Lentivirus-mediated microRNA-26a overexpression in bone mesenchymal stem cells facilitates bone regeneration in bone defects of calvaria in mice. Mol. Med. Rep., 2018, 18: 5317-5326

[159] Hosseinpour S, et al.. A comparative study of mesoporous silica and mesoporous bioactive glass nanoparticles as non-viral microRNA vectors for osteogenesis. Pharmaceutics, 2022, 14: 2302

[160] Kuang H, et al.. Integrated osteoinductive Factors─ Exosome@ MicroRNA-26a hydrogel enhances bone regeneration. ACS Appl. Mater. Interfaces, 2023, 15: 22805-22816

[161] Zhang X, Li Y, Chen YE, Chen J, Ma PX. Cell-free 3D scaffold with two-stage delivery of miRNA-26a to regenerate critical-sized bone defects. Nat. Commun., 2016, 7 10376

[162] Remy MT, et al.. Rat calvarial bone regeneration by 3D-printed β-tricalcium phosphate incorporating microRNA-200c. ACS Biomater. Sci. Eng., 2021, 7: 4521-4534

[163] Sadowska JM, et al.. A multifunctional scaffold for bone infection treatment by delivery of microRNA therapeutics combined with antimicrobial nanoparticles. Adv. Mater., 2024, 36 2307639

[164] Tian M, et al.. The role of lactoferrin in bone remodeling: evaluation of its potential in targeted delivery and treatment of metabolic bone diseases and orthopedic conditions. Front. Endocrinol., 2023, 14 1218148

[165] Sample SJ, Hao Z, Wilson AP, Muir P. Role of calcitonin gene-related peptide in bone repair after cyclic fatigue loading. PLoS One, 2011, 6: e20386

[166] Sheller MR, et al.. Repair of rabbit segmental defects with the thrombin peptide, TP508. J. Orthop. Res., 2004, 22: 1094-1099

[167] Hedberg EL, et al.. Effect of varied release kinetics of the osteogenic thrombin peptide TP508 from biodegradable, polymeric scaffolds on bone formation in vivo. J. Biomed. Mater. Res. A., 2005, 72: 343-353

[168] Pountos I, et al.. The role of peptides in bone healing and regeneration: a systematic review. BMC Med., 2016, 14: 1-15

[169] Nguyen H, Qian JJ, Bhatnagar RS, Li S. Enhanced cell attachment and osteoblastic activity by P-15 peptide-coated matrix in hydrogels. Biochem. Biophys. Res. Commun., 2003, 311: 179-186

[170] Durrieu M-C, et al.. Grafting RGD containing peptides onto hydroxyapatite to promote osteoblastic cells adhesion. J. Mater. Sci. Mater. Med., 2004, 15: 779-786

[171] Kantlehner M, et al.. Surface coating with cyclic RGD peptides stimulates osteoblast adhesion and proliferation as well as bone formation. Chembiochem, 2000, 1: 107-114

[172] Hou T, et al.. A composite demineralized bone matrix–self assembling peptide scaffold for enhancing cell and growth factor activity in bone marrow. Biomaterials, 2014, 35: 5689-5699

[173] Zhang S. Emerging biological materials through molecular self-assembly. Biotechnol. Adv., 2002, 20: 321-339

[174] Han Q-Q, Du Y, Yang P-S. The role of small molecules in bone regeneration. Future Med. Chem., 2013, 5: 1671-1684

[175] Laurencin CT, Ashe KM, Henry N, Kan HM, Lo KW-H. Delivery of small molecules for bone regenerative engineering: preclinical studies and potential clinical applications. Drug Discov. Today, 2014, 19: 794-800

[176] Blaich, G., Janssen, B., Roth, G. & Salfeld, J. Overview: differentiating issues in the development of macromolecules compared with small molecules. Handbook Pharm. Biotechnol. 89–123 (2007).

[177] WH Lo K, D. Ulery B, Deng M, M. Ashe K, T. Laurencin C. Current patents on osteoinductive molecules for bone tissue engineering. Recent Pat. Biomed. Eng., 2011, 4: 153-167

[178] Lo KW, Ashe KM, Kan HM, Laurencin CT. The role of small molecules in musculoskeletal regeneration. Regen. Med., 2012, 7: 535-549

[179] Hojo H, et al.. Development of high-throughput screening system for osteogenic drugs using a cell-based sensor. Biochem. Biophys. Res. Commun., 2008, 376: 375-379

[180] Brey DM, et al.. High-throughput screening of a small molecule library for promoters and inhibitors of mesenchymal stem cell osteogenic differentiation. Biotechnol. Bioeng., 2011, 108: 163-174

[181] Vrijens K, et al.. Identification of small molecule activators of BMP signaling. PLoS One, 2013, 8: e59045

[182] Du Z, Chen J, Yan F, Xiao Y. Effects of Simvastatin on bone healing around titanium implants in osteoporotic rats. Clin. Oral. implants Res., 2009, 20: 145-150

[183] Yang, G. et al. Bone responses to simvastatin-loaded porous implant surfaces in an ovariectomized model. Int. J. Oral Maxillofac. Implants27, 369−374 (2012).

[184] Montgomery SR, et al.. A novel osteogenic oxysterol compound for therapeutic development to promote bone growth: activation of hedgehog signaling and osteogenesis through smoothened binding. J. Bone Miner. Res., 2014, 29: 1872-1885

[185] Aronin CEP, et al.. The enhancement of bone allograft incorporation by the local delivery of the sphingosine 1-phosphate receptor targeted drug FTY720. Biomaterials, 2010, 31: 6417-6424

[186] Huang C, et al.. Local delivery of FTY720 accelerates cranial allograft incorporation and bone formation. Cell Tissue Res., 2012, 347: 553-566

[187] Heilmann A, et al.. Systemic treatment with the sphingosine-1-phosphate analog FTY720 does not improve fracture healing in mice. J. Orthop. Res., 2013, 31: 1845-1850

[188] Thomson A, Bonham C, Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther. Drug Monit., 1995, 17: 584-591

[189] De la Vega R, et al.. Effects of FK506 on the healing of diaphyseal, critical size defects in the rat femur. Eur. Cells Mater., 2020, 40: 160

[190] Wong E, et al.. A novel low-molecular-weight compound enhances ectopic bone formation and fracture repair. JBJS, 2013, 95: 454-461

[191] Stadelmann VA, Terrier A, Gauthier O, Bouler J-M, Pioletti DP. Implants delivering bisphosphonate locally increase periprosthetic bone density in an osteoporotic sheep model. A pilot study. Eur. Cells Mater., 2008, 16: 10-16

[192] Zhang Q, et al.. Small-molecule amines: a big role in the regulation of bone homeostasis. Bone Res., 2023, 11: 40

[193] Patterson TE, Kumagai K, Griffith L, Muschler GF. Cellular strategies for enhancement of fracture repair. JBJS, 2008, 90: 111-119

[194] Virk MS, Lieberman JR. Biologic adjuvants for fracture healing. Arthritis Res. Ther., 2012, 14: 1-13

[195] Giordano A, Galderisi U, Marino IR. From the laboratory bench to the patient’s bedside: an update on clinical trials with mesenchymal stem cells. J. Cell. Physiol., 2007, 211: 27-35

[196] Tsuji W, Rubin JP, Marra KG. Adipose-derived stem cells: implications in tissue regeneration. World J. Stem Cells, 2014, 6: 312

[197] Marcacci M, et al.. Stem cells associated with macroporous bioceramics for long bone repair: 6-to 7-year outcome of a pilot clinical study. Tissue Eng., 2007, 13: 947-955

[198] Quarto R, et al.. Repair of large bone defects with the use of autologous bone marrow stromal cells. N. Engl. J. Med., 2001, 344: 385-386

[199] Kim S-J, et al.. A multi-center, randomized, clinical study to compare the effect and safety of autologous cultured osteoblast (Ossron™) injection to treat fractures. BMC Musculoskelet. Disord., 2009, 10: 1-9

[200] Goel A, Sangwan S, Siwach R, Ali AM. Percutaneous bone marrow grafting for the treatment of tibial non-union. Injury, 2005, 36: 203-206

[201] Kettunen J, Mäkelä E, Turunen V, Suomalainen O, Partanen K. Percutaneous bone grafting in the treatment of the delayed union and non-union of tibial fractures. Injury, 2002, 33: 239-245

[202] Chen H, Liu O, Chen S, Zhou Y. Aging and mesenchymal stem cells: therapeutic opportunities and challenges in the older group. Gerontology, 2022, 68: 339-352

[203] Widholz B, Tsitlakidis S, Reible B, Moghaddam A, Westhauser F. Pooling of patient-derived mesenchymal stromal cells reduces inter-individual confounder-associated variation without negative impact on cell viability, proliferation and osteogenic differentiation. Cells, 2019, 8: 633

[204] Sato Y, et al.. Tumorigenicity assessment of cell therapy products: the need for global consensus and points to consider. Cytotherapy, 2019, 21: 1095-1111

[205] Alsousou J, Thompson M, Hulley P, Noble A, Willett K. The biology of platelet-rich plasma and its application in trauma and orthopaedic surgery: a review of the literature. J. Bone Jt. Surg. Br., 2009, 91: 987-996

[206] Sánchez M, et al.. Comparison of surgically repaired Achilles tendon tears using platelet-rich fibrin matrices. Am. J. sports Med., 2007, 35: 245-251

[207] Sánchez, A. R., Sheridan, P. J. & Kupp, L. I. Is platelet-rich plasma the perfect enhancement factor? A current review. Int. J. Oral Maxillofac. Implants18, 93−103 (2003).

[208] Oryan A, Alidadi S, Moshiri A. Platelet-rich plasma for bone healing and regeneration. Expert Opin. Biol. Ther., 2016, 16: 213-232

[209] Sys J, Weyler J, Van Der Zijden T, Parizel P, Michielsen J. Platelet-rich plasma in mono-segmental posterior lumbar interbody fusion. Eur. Spine J., 2011, 20: 1650-1657

[210] Peerbooms JC, et al.. No positive bone healing after using platelet rich plasma in a skeletal defect. An observational prospective cohort study. Int. Orthop., 2012, 36: 2113-2119

[211] Abagnale G, et al.. Surface topography enhances differentiation of mesenchymal stem cells towards osteogenic and adipogenic lineages. Biomaterials, 2015, 61: 316-326

[212] Sadowska JM, et al.. Development of miR-26a-activated scaffold to promote healing of critical-sized bone defects through angiogenic and osteogenic mechanisms. Biomaterials, 2023, 303 122398

[213] Liu Y, et al.. Sustained delivery of a heterodimer bone morphogenetic protein-2/7 via a collagen hydroxyapatite scaffold accelerates and improves critical femoral defect healing. Acta Biomater., 2023, 162: 164-181

[214] Kim S, et al.. Sequential delivery of BMP-2 and IGF-1 using a chitosan gel with gelatin microspheres enhances early osteoblastic differentiation. Acta Biomater., 2012, 8: 1768-1777

[215] Xin T, et al.. Programmed sustained release of recombinant human bone morphogenetic protein-2 and inorganic ion composite hydrogel as artificial periosteum. ACS Appl. Mater. interfaces, 2020, 12: 6840-6851

[216] Zhao C, et al.. The role of the micro-pattern and nano-topography of hydroxyapatite bioceramics on stimulating osteogenic differentiation of mesenchymal stem cells. Acta Biomater., 2018, 73: 509-521

[217] Kang Y, Kim S, Khademhosseini A, Yang Y. Creation of bony microenvironment with CaP and cell-derived ECM to enhance human bone-marrow MSC behavior and delivery of BMP-2. Biomaterials, 2011, 32: 6119-6130

[218] Chandrakar A, et al.. Melt electrowriting of hydrophilic/hydrophobic multiblock copolymers for bone tissue regeneration. Biomater. Adv., 2025, 169 214167

[219] Sanchez, A. A. et al. Enhanced osteogenic differentiation in hyaluronic acid methacrylate (HAMA) matrix: a comparative study of hPDC and hBMSC spheroids for bone tissue engineering. Biofabrication17, 025013 (2025).

[220] van der Heide, D. et al. implementing bmp-7 chemically modified RNA for bone regeneration with 3D printable hyaluronic acid-collagen granular gels. Adv. Healthcare Mater.14, 2405047 (2025).

[221] Alejandro P, Constantinescu F. A review of osteoporosis in the older adult. Clin. Geriatr. Med., 2017, 33: 27-40

[222] Center, J. R. Outcomes following osteoporotic fractures. In Osteoporosis (fourth edition) 841–852 (2013).

[223] Langdahl BL. Overview of treatment approaches to osteoporosis. Br. J. Pharm., 2020, 178: 1891-1906

[224] Office of the Surgeon General (US). Bone Health and Osteoporosis: A Report of the Surgeon General. The Burden of Bone Disease. (Rockville (MD), 2004).

[225] Cummings SR, et al.. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med., 2009, 361: 756-765

[226] Lyu, Q. Therapeutic potential of nucleic acid aptamers against sclerostin in the treatment of osteoporosis, Hong Kong Baptist University, (2017).

[227] Laine CM, et al.. WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta. N. Engl. J. Med., 2013, 368: 1809-1816

[228] Houschyar KS, et al.. Wnt pathway in bone repair and regeneration–what do we know so far. Front. Cell Dev. Biol., 2019, 6: 170

[229] Egermann M, et al.. Direct adenoviral transfer of bone morphogenetic protein-2 cDNA enhances fracture healing in osteoporotic sheep. Hum. Gene Ther., 2006, 17: 507-517

[230] Zeng Y, et al.. Gene therapy with Tetracycline-regulated human recombinant COLIA1 cDNA direct adenoviral delivery enhances fracture healing in osteoporotic rats. Hum. Gene Ther., 2018, 29: 902-915

[231] Tang Y, et al.. Combination of bone tissue engineering and BMP-2 gene transfection promotes bone healing in osteoporotic rats. Cell Biol. Int., 2008, 32: 1150-1157

[232] Liu J, et al.. Delivery of m7G methylated Runx2 mRNA by bone-targeted lipid nanoparticle promotes osteoblastic bone formation in senile osteoporosis. Nano Today, 2024, 54: 102074

[233] Michigami T. Rickets/Osteomalacia. Consensus on vitamin D deficiency and insufficiency in children. Clin. Calcium, 2018, 28: 1307-1311

[234] Sahay M, Sahay R. Rickets–vitamin D deficiency and dependency. Indian J. Endocrinol. Metab., 2012, 16: 164

[235] Francis RM, Selby PL. Osteomalacia. Bailliere’s. Clin. Endocrinol. Metab., 1997, 11: 145-163

[236] Land C, Schoenau E. Fetal and postnatal bone development: reviewing the role of mechanical stimuli and nutrition. Best. Pract. Res. Clin. Endocrinol. Metab., 2008, 22: 107-118

[237] Acar S, Demir K, Shi Y. Genetic causes of rickets. J. Clin. Res. Pediatr. Endocrinol., 2017, 9: 88

[238] Beck-Nielsen SS, et al.. FGF23 and its role in X-linked hypophosphatemia-related morbidity. Orphanet J. Rare Dis., 2019, 14: 1-25

[239] Bai X, Levental M, Karaplis AC. Burosumab treatment for autosomal recessive hypophosphatemic rickets type 1 (ARHR1). J. Clin. Endocrinol. Metab., 2022, 107: 2777-2783

[240] Mornet E. Hypophosphatasia. Metabolism, 2018, 82: 142-155

[241] Kang M, Wu M, Crane JL. Asfotase alfa improved skeletal mineralization and fracture healing in a child with MCAHS. Bone, 2023, 172: 116778

[242] Dardenne O, Prud’homme JE, Arabian A, Glorieux FH, St-Arnaud R. Targeted inactivation of the 25-hydroxyvitamin D3-1α-hydroxylase gene (CYP27B1) creates an animal model of pseudovitamin D-deficiency rickets. Endocrinology, 2001, 142: 3135-3141

[243] Fukumoto S. FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment. J. Mol. Endocrinol., 2021, 66: R57-R65

[244] Siris ES. Paget’s disease of bone. J. Bone Miner. Res., 1998, 13: 1061-1065

[245] Friedrichs WE, et al.. Sequence analysis of measles virus nucleocapsid transcripts in patients with Paget’s disease. J. Bone Miner. Res., 2002, 17: 145-151

[246] Singer FR. Paget’s disease of bone—genetic and environmental factors. Nat. Rev. Endocrinol., 2015, 11: 662

[247] Singer, F., Schiller, A. & Pyle, E. Paget’s disease of bone. Metabolic Bone Disease2, 489−575 (1978).

[248] Naot D, et al.. Differential gene expression in cultured osteoblasts and bone marrow stromal cells from patients with Paget’s disease of bone. J. Bone Miner. Res., 2007, 22: 298-309

[249] Xia Z, Chen C, Chen P, Xie H, Luo X. MicroRNAs and their roles in osteoclast differentiation. Front. Med., 2011, 5: 414-419

[250] Forlino A, Marini JC. Osteogenesis imperfecta. Lancet, 2016, 387: 1657-1671

[251] Ralston SH, Gaston MS. Management of Osteogenesis Imperfecta. Front Endocrinol, 2019, 10: 924

[252] Agarwal V, Joseph B. Non-union in osteogenesis imperfecta. J. Pediatr. Orthop. B, 2005, 14: 451-455

[253] Roschger P, et al.. Evidence that abnormal high bone mineralization in growing children with osteogenesis imperfecta is not associated with specific collagen mutations. Calcif. Tissue Int., 2008, 82: 263-270

[254] Niyibizi C, Wang S, Mi Z, Robbins P. Gene therapy approaches for osteogenesis imperfecta. Gene Ther., 2004, 11: 408-416

[255] Horwitz EM, et al.. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc. Natl. Acad. Sci., 2002, 99: 8932-8937

[256] Cardinal M, et al.. Sclerostin antibody reduces long bone fractures in the oim/oim model of osteogenesis imperfecta. Bone, 2019, 124: 137-147

[257] Glorieux FH, et al.. BPS804 anti-sclerostin antibody in adults with moderate osteogenesis imperfecta: results of a randomized phase 2a trial. J. Bone Miner. Res., 2017, 32: 1496-1504

[258] Melton LJIII, Kyle RA, Achenbach SJ, Oberg AL, Rajkumar SV. Fracture risk with multiple myeloma: a population-based study. J. Bone Miner. Res., 2005, 20: 487-493

[259] Bryson DJ, Wicks L, Ashford RU. The investigation and management of suspected malignant pathological fractures: a review for the general orthopaedic surgeon. Injury, 2015, 46: 1891-1899

[260] Tsuzuki S, Park SH, Eber MR, Peters CM, Shiozawa Y. Skeletal complications in cancer patients with bone metastases. Int. J. Urol., 2016, 23: 825-832

[261] Castañeda S, et al.. Bone loss induced by cancer treatments in breast and prostate cancer patients. Clin. Transl. Oncol., 2022, 24: 2090-2106

[262] Hamouda AE, et al.. Intratumoral delivery of lipid nanoparticle-formulated mRNA encoding IL-21, IL-7, and 4-1BBL induces systemic anti-tumor immunity. Nat. Commun., 2024, 15: 1-20

[263] Wang L, et al.. A clinical study on bone defect reconstruction and functional recovery in benign bone tumors of the lower extremity, treated by bone marrow mesenchymal stem cell rapid screening–enrichment–composite system. World J. Surg. Oncol., 2021, 19: 1-7

[264] Bostrom MP, et al.. Immunolocalization and expression of bone morphogenetic proteins 2 and 4 in fracture healing. J. Orthop. Res., 1995, 13: 357-367

[265] Gillman CE, Jayasuriya AC. FDA-approved bone grafts and bone graft substitute devices in bone regeneration. Mater. Sci. Eng. C., 2021, 130: 112466

[266] Eppley BL, Doucet M, Connolly DT, Feder J. Enhancement of angiogenesis by bFGF in mandibular bone graft healing in the rabbit. J. oral. Maxillofac. Surg., 1988, 46: 391-398

[267] Kawaguchi H, et al.. A local application of recombinant human fibroblast growth factor 2 for tibial shaft fractures: A randomized, placebo-controlled trial. J. Bone Miner. Res., 2010, 25: 2735-2743

[268] Daniels TR, et al.. Prospective randomized controlled trial of hindfoot and ankle fusions treated with rhPDGF-BB in combination with a β-TCP-collagen matrix. Foot Ankle Int., 2015, 36: 739-748

[269] Joyce ME, Roberts AB, Sporn MB, Bolander ME. Transforming growth factor-beta and the initiation of chondrogenesis and osteogenesis in the rat femur. J. Cell Biol., 1990, 110: 2195-2207

[270] Xu J, et al.. High-dose TGF-β1 impairs mesenchymal stem cell–mediated bone regeneration via Bmp2 inhibition. J. Bone Miner. Res., 2020, 35: 167-180

[271] Boonen S, et al.. Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: a double-blind, placebo-controlled pilot study. J. Clin. Endocrinol. Metab., 2002, 87: 1593-1599

[272] Street J, et al.. Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc. Natl. Acad. Sci., 2002, 99: 9656-9661

[273] Peng H, et al.. Synergistic enhancement of bone formation and healing by stem cell–expressed VEGF and bone morphogenetic protein-4. J. Clin. Invest., 2002, 110: 751-759

[274] Hu K, Olsen BR. Osteoblast-derived VEGF regulates osteoblast differentiation and bone formation during bone repair. J. Clin. Invest., 2016, 126: 509-526

[275] Yang P, et al.. rhVEGF165 delivered in a porous β-tricalcium phosphate scaffold accelerates bridging of critical-sized defects in rabbit radii. J. Biomed. Mater. Res. A, 2010, 92: 626-640

[276] Zhang L, et al.. Improvement in angiogenesis and osteogenesis with modified cannulated screws combined with VEGF/PLGA/fibrin glue in femoral neck fractures. J. Mater. Sci.: Mater. Med., 2014, 25: 1165-1172

[277] Quinlan E, et al.. Controlled release of vascular endothelial growth factor from spray-dried alginate microparticles in collagen–hydroxyapatite scaffolds for promoting vascularization and bone repair. J. tissue Eng. Regen. Med., 2017, 11: 1097-1109

[278] Rivera KO, et al.. Local injections of β-NGF accelerates endochondral fracture repair by promoting cartilage to bone conversion. Sci. Rep., 2020, 10 22241

[279] Wang Z, et al.. A regulatory loop containing miR-26a, GSK3β and C/EBPα regulates the osteogenesis of human adipose-derived mesenchymal stem cells. Sci. Rep., 2015, 5 15280

[280] Yang C, et al.. miRNA-21 promotes osteogenesis via the PTEN/PI3K/Akt/HIF-1α pathway and enhances bone regeneration in critical size defects. Stem Cell Res. Ther., 2019, 10: 1-11

[281] Krist B, Florczyk U, Pietraszek-Gremplewicz K, Józkowicz A, Dulak J. The role of miR-378a in metabolism, angiogenesis, and muscle biology. Int. J. Endocrinol., 2015, 2015: 281756

[282] You L, et al.. MiR-378 overexpression attenuates high glucose-suppressed osteogenic differentiation through targeting CASP3 and activating PI3K/Akt signaling pathway. Int. J. Clin. Exp. Pathol., 2014, 7: 7249

[283] Zhang B, et al.. MicroRNA-378 promotes osteogenesis-angiogenesis coupling in BMMSCs for potential bone regeneration. Anal. Cell. Pathol., 2018, 2018 8402390

[284] Tian Z, Zhou H, Xu Y, Bai J. MicroRNA-495 inhibits new bone regeneration via targeting high mobility group AT-Hook 2 (HMGA2). Med. Sci. Monit. Int. Med. J. Exp. Clin. Res., 2017, 23: 4689

[285] Minamizaki T, et al.. The matrix vesicle cargo miR-125b accumulates in the bone matrix, inhibiting bone resorption in mice. Commun. Biol., 2020, 3: 30

[286] Joris, V., Balmayor, E. R. & van Griensven, M. miR-125b differentially impacts mineralization in dexamethasone and calcium-treated human mesenchymal stem cells. Mol. Ther. Nucleic Acids36, 102446 (2025).

[287] Ito S, et al.. Overexpression of miR-125b in osteoblasts improves age-related changes in bone mass and quality through suppression of osteoclast formation. Int. J. Mol. Sci., 2021, 22: 6745

[288] Zhang W, et al.. miRNA-133a-5p inhibits the expression of osteoblast differentiation-associated markers by targeting the 3′ UTR of RUNX2. DNA Cell Biol., 2018, 37: 199-209

[289] Miscianinov V, et al.. MicroRNA-148b targets the TGF-β pathway to regulate angiogenesis and endothelial-to-mesenchymal transition during skin wound healing. Mol. Ther., 2018, 26: 1996-2007

[290] Moncal KK, et al.. Collagen-infilled 3D printed scaffolds loaded with miR-148b-transfected bone marrow stem cells improve calvarial bone regeneration in rats. Mater. Sci. Eng. C., 2019, 105 110128

[291] Mollazadeh S, et al.. Overexpression of MicroRNA-148b-3p stimulates osteogenesis of human bone marrow-derived mesenchymal stem cells: the role of MicroRNA-148b-3p in osteogenesis. BMC Med. Genet., 2019, 20: 1-10

Funding

EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)(874790)

RIGHTS & PERMISSIONS

The Author(s)